^**A double-blind, randomized study of 1,443 patients who received early treatment for 5 days. Subjects were required to have experienced ulcerative lesions in 75% of cold sore episodes in past year.<sup>1

†</sup>A multicenter, randomized, double-blind, active and placebo-controlled study involving 2,437 patients with a history of HSL. Patients were randomized to self initiate treatment with XERESE, 5% acyclovir in XERESE vehicle, or XERESE vehicle (placebo) at the earliest sign of a cold sore recurrence.²

1. XERESE^® (acyclovir and hydrocortisone) cream 5%/1% Prescribing Information. January, 2014.
2. Data on file. Valeant Dermatology.

*This offer is only valid for patients with commercial insurance. Eligible uninsured patients will pay more. This offer is not valid for any person eligible for reimbursement of prescriptions, in whole or in part, by any federal, state, or other governmental programs, including, but not limited to, Medicare (including Medicare Advantage and Part A, B, and D plans), Medicaid, TRICARE, Veterans Administration or Department of Defense health coverage, CHAMPUS, the Puerto Rico Government Health Insurance Plan, or any other federal or state health care programs. This offer is good only in the U.S. at retail pharmacies owned and operated by Walgreen Co. (or its affiliates) or other participating independent retail pharmacies. This offer is not valid in Massachusetts or Minnesota or where otherwise prohibited, taxed or otherwise restricted. Click here for other terms and conditions that apply.